{"protocolSection": {"identificationModule": {"nctId": "NCT00960076", "orgStudyIdInfo": {"id": "D1680L00005"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes", "officialTitle": "18-Week, Multicenter, Randomized, Double-Blind 3b Trial to Evaluate Efficacy/Safety of Saxagliptin in Combo With Metformin XR 1500mg vs Metformin Uptitrated to 2000mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control After Diet/Exercise and a Stable Dose of Metformin XR 1500mg", "acronym": "SCORE"}, "statusModule": {"statusVerifiedDate": "2011-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-08"}, "primaryCompletionDateStruct": {"date": "2010-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-08-14", "studyFirstSubmitQcDate": "2009-08-14", "studyFirstPostDateStruct": {"date": "2009-08-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-06-30", "resultsFirstSubmitQcDate": "2011-08-22", "resultsFirstPostDateStruct": {"date": "2011-09-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-08-22", "lastUpdatePostDateStruct": {"date": "2011-09-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["T2DM", "Metformin", "A1c"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 282, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Saxagliptin", "interventionNames": ["Drug: Saxagliptin", "Drug: Metformin XR"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Metformin Extended Release", "interventionNames": ["Drug: Metformin XR"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "5mg oral tablet once daily", "armGroupLabels": ["1"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "Metformin XR", "description": "500mg oral tablet once daily", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "Metformin XR", "description": "750mg, 2 tablets once daily", "armGroupLabels": ["1", "2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in HbA1c Level From Baseline to Week 18 (LOCF)", "description": "Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.", "timeFrame": "Baseline to week 18"}], "secondaryOutcomes": [{"measure": "Change in 2-hour PPG Following Mixed Meal Tolerance Test (MMTT) From Baseline to Week 18 (LOCF)", "description": "Adjusted mean change from baseline in 2-hour PPG (following MMTT) achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). PPG is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.", "timeFrame": "Baseline to week 18"}, {"measure": "Change in FPG From Baseline to Week 18 (LOCF)", "description": "Adjusted mean change from baseline in FPG achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). FPG is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.", "timeFrame": "Baseline to week 18"}, {"measure": "Percent of Subjects Reaching Goal (HbA1c <7%) at Week 18 (LOCF) - Percent of Subjects (1)", "description": "Percent of subjects achieving therapeutic response (HbA1c \\<7.0%) at Week 18 (LOCF) (Randomized analysis set)", "timeFrame": "Week 18 (LOCF)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetics taking metformin IR or XR greater than or equal to 850mg and less than or equal to 1500mg only for at least 8 weeks prior to screening\n* A1c: 7.5-11% (at screening)\n* BMI less than or equal to 45 kg/m2\n\nExclusion Criteria:\n\n* Significant cardiovascular history\n* Active liver disease, renal impairment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boaz Hirschberg, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}, {"name": "Vivian Fonseca, MD", "affiliation": "Tulane University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Jonesboro", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 35.8423, "lon": -90.70428}}, {"facility": "Research Site", "city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Research Site", "city": "Fountain Valley", "state": "California", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Pasadena", "state": "California", "country": "United States", "geoPoint": {"lat": 34.14778, "lon": -118.14452}}, {"facility": "Research Site", "city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Research Site", "city": "Gainesville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Research Site", "city": "Wellington", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.65868, "lon": -80.24144}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Springfield", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "Research Site", "city": "Indianapolis", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Research Site", "city": "St Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Salisbury", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.67097, "lon": -80.47423}}, {"facility": "Research Site", "city": "Wilmington", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "Research Site", "city": "Winston-salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Columbus", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Research Site", "city": "Marion", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 40.58867, "lon": -83.12852}}, {"facility": "Research Site", "city": "Simpsonville", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.73706, "lon": -82.25428}}, {"facility": "Research Site", "city": "Bristol", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "Research Site", "city": "Alexandria", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.80484, "lon": -77.04692}}, {"facility": "Research Site", "city": "Burke", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.79345, "lon": -77.27165}}, {"facility": "Research Site", "city": "Manassas", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.75095, "lon": -77.47527}}, {"facility": "Research Site", "city": "Barranquilla", "state": "Atlantico", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Research Site", "city": "Barranquilla", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Research Site", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Research Site", "city": "Curridabat", "state": "San Jose", "country": "Costa Rica", "geoPoint": {"lat": 9.91179, "lon": -84.03407}}, {"facility": "Research Site", "city": "Los Yoses", "state": "San Jose", "country": "Costa Rica", "geoPoint": {"lat": 9.9306, "lon": -84.06043}}, {"facility": "Research Site", "city": "Heredia", "country": "Costa Rica", "geoPoint": {"lat": 10.00236, "lon": -84.11651}}, {"facility": "Research Site", "city": "Mexico", "state": "D.f.", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Research Site", "city": "Guadalajara", "state": "Jalisco", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Zapopan", "state": "Jalisco", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Research Site", "city": "Cuernavaca", "state": "Morelos", "country": "Mexico", "geoPoint": {"lat": 18.9261, "lon": -99.23075}}, {"facility": "Research Site", "city": "Durango", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Research Site", "city": "Queretaro", "country": "Mexico"}, {"facility": "Research Site", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}]}, "referencesModule": {"references": [{"pmid": "22192246", "type": "DERIVED", "citation": "Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012 Apr;14(4):365-71. doi: 10.1111/j.1463-1326.2011.01553.x. Epub 2012 Jan 18."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 393 subjects who entered the lead-in period, 111 subjects did not enter the randomized, double-blind treatment period. Thus, a total of 282 subjects were randomized and treated.", "groups": [{"id": "FG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg (DB) + Metformin XR 1500 mg (OL)"}, {"id": "FG001", "title": "Metformin (DB) + Metformin (OL)", "description": "Metformin XR 500 mg (DB) + Metformin XR 1500 mg (OL)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized and treated", "numSubjects": "138"}, {"groupId": "FG001", "comment": "Randomized and treated", "numSubjects": "144"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Completing 18 weeks of treatment", "numSubjects": "130"}, {"groupId": "FG001", "comment": "Completing 18 weeks of treatment", "numSubjects": "119"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "25"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "No longer met study criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Severe non-compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Hyperglycemia", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Did not attend the termination visit", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg (DB) + Metformin XR 1500 mg (OL)"}, {"id": "BG001", "title": "Metformin (DB) + Metformin (OL)", "description": "Metformin XR 500 mg (DB) + Metformin XR 1500 mg (OL)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "144"}, {"groupId": "BG002", "value": "282"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.22", "spread": "9.41"}, {"groupId": "BG001", "value": "55.46", "spread": "9.86"}, {"groupId": "BG002", "value": "55.34", "spread": "9.64"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "152"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "130"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in HbA1c Level From Baseline to Week 18 (LOCF)", "description": "Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "Baseline to week 18", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg (DB) + Metformin XR 1500 mg (OL)"}, {"id": "OG001", "title": "Metformin (DB) + Metformin (OL)", "description": "Metformin XR 500 mg (DB) + Metformin XR 1500 mg (OL)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "142"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.41", "spread": "0.076"}, {"groupId": "OG001", "value": "8.28", "spread": "0.077"}]}]}, {"title": "Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.53", "spread": "0.093"}, {"groupId": "OG001", "value": "7.93", "spread": "0.111"}]}]}, {"title": "Adjusted Change from Baseline to Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.88", "spread": "0.077"}, {"groupId": "OG001", "value": "-0.35", "spread": "0.076"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-0.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.73", "ciUpperLimit": "-0.31", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.108"}]}, {"type": "SECONDARY", "title": "Change in 2-hour PPG Following Mixed Meal Tolerance Test (MMTT) From Baseline to Week 18 (LOCF)", "description": "Adjusted mean change from baseline in 2-hour PPG (following MMTT) achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). PPG is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to week 18", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg (DB) + Metformin XR 1500 mg (OL)"}, {"id": "OG001", "title": "Metformin (DB) + Metformin (OL)", "description": "Metformin XR 500 mg (DB) + Metformin XR 1500 mg (OL)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "117"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "227.36", "spread": "6.022"}, {"groupId": "OG001", "value": "223.68", "spread": "5.295"}]}]}, {"title": "Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "195.11", "spread": "5.876"}, {"groupId": "OG001", "value": "216.24", "spread": "6.230"}]}]}, {"title": "Adjusted Change from Baseline to Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.52", "spread": "4.996"}, {"groupId": "OG001", "value": "-8.20", "spread": "5.081"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-23.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-37.36", "ciUpperLimit": "-9.28", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.128"}]}, {"type": "SECONDARY", "title": "Change in FPG From Baseline to Week 18 (LOCF)", "description": "Adjusted mean change from baseline in FPG achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). FPG is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to week 18", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg (DB) + Metformin XR 1500 mg (OL)"}, {"id": "OG001", "title": "Metformin (DB) + Metformin (OL)", "description": "Metformin XR 500 mg (DB) + Metformin XR 1500 mg (OL)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "142"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "162.54", "spread": "4.146"}, {"groupId": "OG001", "value": "163.35", "spread": "3.910"}]}]}, {"title": "Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "142.70", "spread": "3.633"}, {"groupId": "OG001", "value": "156.32", "spread": "3.948"}]}]}, {"title": "Adjusted Change from Baseline to Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.03", "spread": "3.146"}, {"groupId": "OG001", "value": "-6.85", "spread": "3.090"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-13.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.86", "ciUpperLimit": "-4.50", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.409"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Reaching Goal (HbA1c <7%) at Week 18 (LOCF) - Percent of Subjects (1)", "description": "Percent of subjects achieving therapeutic response (HbA1c \\<7.0%) at Week 18 (LOCF) (Randomized analysis set)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 18 (LOCF)", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg (DB) + Metformin XR 1500 mg (OL)"}, {"id": "OG001", "title": "Metformin (DB) + Metformin (OL)", "description": "Metformin XR 500 mg (DB) + Metformin XR 1500 mg (OL)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "37.2"}, {"groupId": "OG001", "value": "26.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0459", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "11.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.2", "ciUpperLimit": "22.0"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg (DB) + Metformin XR 1500 mg (OL)", "seriousNumAffected": 0, "seriousNumAtRisk": 138, "otherNumAffected": 21, "otherNumAtRisk": 138}, {"id": "EG001", "title": "Metformin (DB) + Metformin (OL)", "description": "Metformin XR 500 mg (DB) + Metformin XR 1500 mg (OL)", "seriousNumAffected": 3, "seriousNumAtRisk": 144, "otherNumAffected": 16, "otherNumAtRisk": 144}], "seriousEvents": [{"term": "Arteriosclerosis coronary artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 144}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 144}]}, {"term": "Duodenal ulcer perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 144}]}], "otherEvents": [{"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 144}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 144}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 144}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}